Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac N : Shareholder dievini Files Shareholding Change with US Regulator; Stock Down 5%

10/18/2021 | 06:46am EST


ę MT Newswires 2021
All news about CUREVAC N.V.
11/30GSK names Pfizer scientist Dormitzer as vaccines R&D head
RE
11/19CureVac's Q3 Pretax Loss Widens, Revenue Rises
MT
11/19CureVac To Begin Trials Of COVID-19 Vaccine As Animal Testing Shows Strong Antibody Res..
MT
11/18CureVac to begin trials for next-generation COVID-19 shots within months
RE
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021..
EQ
11/18CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2C..
MT
11/18CUREVAC N : Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
PU
11/18CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
EQ
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 140 M 158 M 158 M
Net income 2021 -401 M -454 M -454 M
Net cash 2021 1 249 M 1 413 M 1 413 M
P/E ratio 2021 -16,7x
Yield 2021 -
Capitalization 5 945 M 6 726 M 6 726 M
EV / Sales 2021 33,6x
EV / Sales 2022 1,86x
Nbr of Employees 505
Free-Float 45,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 38,52 €
Average target price 56,82 €
Spread / Average Target 47,5%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-46.19%6 726
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298